Page last updated: 2024-08-05 11:02:03

phenanthridines

Any dibenzopyridine based on the skeleton of phenanthridine and its substituted derivatives thereof.

ChEBI ID: 51245

Members (16)

MemberDefinitionRole
2-[(2,3-dimethyl-7,8,9,10-tetrahydrophenanthridin-6-yl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide2-[(2,3-dimethyl-7,8,9,10-tetrahydrophenanthridin-6-yl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide
5H-phenanthridine-6-thione5H-phenanthridine-6-thione
7-deoxypancratistatin7-Deoxypancratistatin
anhydrolycorinoneAnhydrolycorinone
cy 208-243LSM-3788
dihydrexidine(6aR,12bS)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol
ethidiumThe fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.ethidium
lycoricidineLycoricidine
narciclasineNarciclasine
nitidineNitidine
phenanthridineAn azaarene that is the 9-aza derivative of phenanthrene. The parent of the class of phenanthridines.phenanthridine
phenanthridoneA member of the class of phenanthridines that is phenanthridine with an oxo substituent at position 6. A poly(ADP-ribose) polymerase (PARP) inhibitor, it has been shown to exhibit immunosuppressive activity.phenanthridone
pj-34A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.PJ34
propidiumpropidium
pseudolycorinePseudolycorine
trispheridineTrisphaeridine

Research

Studies (7,763)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-19901,968 (25.35)18.7374
1990's1,519 (19.57)18.2507
2000's2,263 (29.15)29.6817
2010's1,706 (21.98)24.3611
2020's307 (3.95)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials28 (0.34%)5.53%
Reviews112 (1.37%)6.00%
Case Studies12 (0.15%)4.05%
Observational2 (0.02%)0.25%
Other8,025 (98.12%)84.16%